key: cord-0334468-wceo0i8r
authors: Violan, C.; Toran, P.; Quirant, B.; Lamonja-Vicente, N.; Carrasco-Ribelles, L. A.; Chacon, C.; Manresa-Dominguez, J. M.; Ramos-Roure, F.; Roso-Llorach, A.; Pujol, A.; Ouchi, D.; Monteagudo, M.; Montero, P.; Garcia-Sierra, R.; Armestar, F.; Dacosta-Aguayo, R.; Dolade, M.; Prat, N.; Bonet, J. M.; Clotet, B.; Blanco, I.; Prado, J. G.; Martinez-Caceres, E. M.; Investigators, ProHEpiC-19
title: Antibody kinetics to SARS-CoV-2 at 13.5 months, by disease severity
date: 2021-09-15
journal: nan
DOI: 10.1101/2021.09.10.21262527
sha: fc6224f4aa37a9a5d7b6ed85efc7cdfd28814001
doc_id: 334468
cord_uid: wceo0i8r

Background: Understanding humoral responses and seroprevalence in SARS-CoV-2 infection is essential for guiding vaccination strategies in both infected and uninfected individuals. Methods: We determine the kinetics of IgM against the nucleocapsid (N) and IgG against the spike (S) and N proteins of SARS-CoV-2 in a cohort of 860 health professionals (healthy and infected) in northern Barcelona. We model the kinetics of IgG and IgM at nine time points over 13.5 months from infection, using non-linear mixed models by sex and clinical disease severity. Results: Of the 781 participants who were followed up, 478 (61.2%) became infected with SARS-CoV-2. Significant differences were found for the three antibodies by disease severity and sex. At day 270 after diagnosis, median IgM(N) levels were already below the positivity threshold in patients with asymptomatic and mild-moderate disease, while IgG(N, S) levels remained positive to days 360 and 270, respectively. Kinetic modelling showed a general rise in both IgM(N) and IgG(N) levels up to day 30, followed by a decay whose rate depended on disease severity. IgG(S) levels increased at day 15 and remained relatively constant over time. Conclusions: We describe kinetic models of IgM(N) and IgG(N, S) SARS-CoV-2 antibodies at 13.5 months from infection and disease spectrum. Our analyses delineate differences in the kinetics of IgM and IgG over a year and differences in the levels of IgM and IgG as early as 15 days from symptoms onset in severe cases. These results can inform public health policies around vaccination criteria.

Infection with SARS-CoV-2 can be determined by measuring the generation of virus-specific antibodies, reflecting an immune response against a recent or previous infection 1 COVID-19 has a broad clinical spectrum, with patients experiencing everything from asymptomatic infections to critical illness. Likewise, the antibody response to SARS-CoV-2 infection is heterogeneous 6 . Few longitudinal studies have performed serological follow-up across the clinical spectrum, and with limited study periods, from 80 to 270 days [2] [3] [4] . An early study reported a rapid rise and subsequent fall of antibodies, which stabilized at later time points, indicating that immunity against SARS-CoV-2 lasted for at least four months after infection 7 . Two later studies extended this protection up to at least six months 8, 2 , while recent estimates venture that it persists for at least a year 9, 10 . However, knowledge of the kinetics and nature of the immune response to SARS-CoV-2 infection is still limited, and larger longitudinal studies are needed to define the half-life of antibodies against SARS-CoV-2 and their respective kinetics. Antibodies developed against the virus are directed to different regions of the spike (S) protein and/or against the nucleocapsid (N) or envelope proteins of SARS-CoV-2 11 . The vaccines are based only in the generation of antibodies against the S protein 12 .

Available reagents in compliance with WHO International Standards for anti-SARS-CoV-2 antibodies allow us to evaluate vaccine efficacy and compare epidemiological and immunological surveillance studies. At the beginning of the pandemic, antibody levels were determined using qualitative assays; the availability of an internationally standardized enzyme immunoassay for the quantitative detection of specific IgG antibodies against the spike protein is recent 13 .

6 SARS-CoV-2 target genes in a single tube. In addition, we conducted a pre-validation study (with six different IVD-CE-approved ELISA tests) and selected commercially available anti-SARS-CoV-2 IgG and IgM anti-N ELISA kits based on their performance. Participants with positive anti-N serology or/and RT-PCR were also tested for antibodies against the spike (S) subunit of SARS-CoV-2 by means of an enzyme immunoassay (ELISA) for the quantitative determination of IgG class antibodies using DECOV1901.

Sample size calculation for healthy and infected cohorts can be found in the supplementary protocol. The total collected sample of 478 infected participants achieves 100% power to detect differences among the means versus the alternative of equal means using an F test, assuming values of α=0.05 and an effect size of η² =0.06. This calculation was carried out using a oneway ANOVA test with sample sizes of 72, 367, and 39 from the three clinical groups whose means were to be compared.

A descriptive analysis was undertaken for all categorical and continuous variables. Missing values were found only in in the following sociodemographic variables: education (3.5%), marital status (4.6%), and nationality (7.5%). For the analysis of serological test results, only available data were used.

The evolution of antibody test results from diagnosis was studied considering both dichotomous (i.e. positive/negative result) and numerical values. For the dichotomous response, a descriptive analysis was performed to study the number of participants with each response pattern over time. The monitoring of antibody values after diagnosis was studied in three ways. First, we stratified antibody levels by days since diagnosis, describing them by boxplots and comparing them using statistical tests. Then, at each timepoint, differences were assessed according to disease severity (Holm-adjusted Dunn's test) and sex (Mann-Whitney U test). Second, we fitted locally estimated scatterplot smoothing models (LOESS), calculating their associated 95% . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 15, 2021. ;  7 confidence intervals (CIs). Finally, non-linear mixed effects models (NLME) were also fitted. In these models, each parameter was assumed to have a fixed and a random effect. Both LOESS and NLME models were first fitted for all patients and then stratified by clinical condition and sex. The estimated NLME curves were used to model IgM and IgG kinetics over time. Model diagnostics were performed with residual analysis, and goodness-of-fit was checked with Akaike and Bayesian information criteria. For these analyses, except for LOESS, time from diagnosis was expressed as a discrete variable, with tests performed within several days after diagnosis imputed to the lowest number in the interval. Therefore, tests performed in the first 14 days since diagnosis are treated as "Day 0" and tests performed between day 360 and 449 (i.e. the last day observed, see Table 1 ) are treated as "Day 360", see Table S1 .

All tests were two-sided. The significance level was set at p < 0.05. All analyses were is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 

A total of 860 participants were recruited, of whom 781 were eligible; 451 (57.7%) tested positive at baseline, and 27 (3.5%) had their first positive SARS-CoV-2 antibody test during follow-up ( Figure S1 , Table 1 ). Differences in the prevalence of specific clinical symptoms according to disease severity and sex are shown in Table S2 . to day 180 of infection, more than 45% of participants tested positive for all antibodies.

However, this proportion decreased from day 180 as the number of participants with positive IgM(N) values fell. By day 270, 12.1% of the participants were negative for all antibody tests, while 87.9% of the participants were at least IgG(N) or IgG(S) positive. As Table 2B shows, 67% of participants still had IgG(N) values over the positive threshold at day 360.

We found a statistically significant difference in all antibody levels between clinical conditions (P<0.001 both overall and pairwise comparisons). There was also a significant difference in is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 15, 2021. ;  9 disease consistently had higher levels of IgG (N, S) than patients with asymptomatic or mildmoderate disease. In terms of sex, there were no significant differences, except at day 30, and at day 60 only for IgG(S), when males showed higher levels than females. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 15, 2021. ; https://doi.org/10.1101/2021.09.10.21262527 doi: medRxiv preprint a generalized rise in antibody levels up to day 30 since diagnosis, followed by a decline. Figures   1A and 1B show that both IgM(N) and IgG(N) levels from day 270 are no longer significantly different from those on day 0. Meanwhile, IgG(S) values ( Figure 1C ) remain constant after an initial rise on day 15. As for differences by clinical condition, throughout the follow-up period since diagnosis, the IgM(N), IgG(N) and IgG(S) levels (see Figure 1D -F, respectively) of patients with severe-critical disease were higher almost to the end of follow-up. Although the IgM(N) and IgG(N) levels of asymptomatic patients were initially higher than those of mildmoderate patients, from day 15 they started to decline. From day 270 onwards, the median IgM(N) values of asymptomatic and mild to moderate patients were already below the threshold considered positive. In the case of median IgG(N) levels, although their decrease was evident from day 60 onwards, on day 360 since diagnosis they were still above the positive threshold across the clinical spectrum. On the other hand, median levels of IgG(S) remained virtually constant throughout the entire follow-up period, regardless of disease severity. Compared to women, men had higher levels of all antibodies analyzed on day 30 and of IgG(N) on day 60.

The kinetics for the IgG isotopes varied between N and S. In relation to the kinetics of the three antibodies stratified by disease severity, both LOESS (Figures 2A, 2C , 2D) and NLME ( Figures 2B, 2D, 2E ) adjustment methods showed a general rise in both IgM(N) and IgG(N) levels up to day 30, followed by a decay whose rate depended on disease severity. IgG(S) levels increased at day 15 and remained relatively constant over time. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 15, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 15, 2021. ;  12 data, connecting results belonging to the same participants. Figures 2B, 2D and 2F show the estimated non-linear mixed-effect (NLME) model curves. Each point corresponds to the mean value at each timepoint. The bars show the mean ± standard deviation interval (NLME). The solid and dashed lines represent the limits of definition and uncertainty, respectively, for considering a positive result. Overall, the level of the antigen response correlated with the severity of the clinical presentation. Table S3 shows the parameters estimated for each component of the NLME curves. For both IgM(N) and IgG(N), levels were significantly higher in severe-critical participants at the beginning of the study, the increase rate was slower in asymptomatic disease, and the decrease rate in both asymptomatic and severe-critical disease was faster than in mild-moderate cases.

Regarding IgG (S) levels, severe-critical participants showed significantly higher values on day 270 than mild-moderate participants. Asymptomatic participants had significantly lower values on day 270, but they were still positive. However, as can be seen in Figure 2F , the levels were practically constant in the three groups. levels is higher in males. The parameters of these NLME curves can be also found in Table S3 . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 15, 2021. ; is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 15, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 15, 2021. ;

The LOESS models enable a description of the trajectories of the antibody levels, while the NLME facilitates the comparison of the average trajectories according to disease severity, accounting for the non-linearity of the antibody levels. The model's goodness-of-fit confirms its validity and explanatory capacity, making ours the first study allowing an estimate of antibody values against SARS-CoV-2, with potential applications in vaccinated people to adjust (re)vaccination criteria. Furthermore, the kinetic model of IgG (S) can be easily adapted for estimating antibody levels using other units by applying the corresponding conversion factors.

Likewise, these models can be adapted to the kinetics calculated in vaccinated people, informing the criteria for revaccination.

This study describes, for the first time to our knowledge, differential, and specific dynamics of is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint To conclude, we monitored three antibodies for just over a year, analyzing their titers and kinetics according to clinical severity and sex. NLME models helped explain the average trajectory across the clinical spectrum at one year, confirming that infected people maintain is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Notes: Each column shows the participants that had each combination of results from the diagnostic test at each timepoint. Column shading highlights the most frequent antibody combinations at each timepoint. For Table 2A , only the records with available results for all three antibodies were used, while for Table 2B all records including (N) antibodies were used. An (N) antibody test is defined as positive if it has a value higher than 1.1, while an IgG(S) antibody test is positive if its value is higher than 40. *These percentages have been calculated using the maximum number of available samples per timepoint (i.e. (N) samples). This information is available at Table S1 . is the author/funder, who has granted medRxiv a license to display the preprint in is the author/funder, who has granted medRxiv a license to display the preprint in is the author/funder, who has granted medRxiv a license to display the preprint in 

The Power of Antibody-Based Surveillance

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity

Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity

SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Humoral Immune Response to SARS-COVID-19

From SARS to SARS-CoV-2, insights on structure, pathogenicity and immunity aspects of pandemic human coronaviruses

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Establishment of the WHO International Standard and Reference Panel for anti-SARS-CoV-2 antibody

The Utility of Specific Antibodies Against SARS-CoV-2 in Laboratory Diagnosis

Rapid decline of neutralizing antibodies is associated with decay of IgM in adults recovered from mild COVID-19

COVID-19: Coronavirus Vaccine Development Updates